Skip to content
November 19, 2026
  • WhatsApp
  • Facebook
  • Twitter
  • Youtube
  • LinkedIn
  • Instagram
Business Quest

Business Quest

Focus on Enterprises and Innovation

  • HOME
  • BUSINESS
    • BANKING
    • FINANCE
    • INSURANCE
    • SME’s
    • REAL ESTATES
    • INVESTMENTS
    • ENERGY
    • RETAIL
  • CAPTAINS OF INDUSTRY
  • INNOVATION & ENTERPRISES
  • WOMEN & POWER
  • TECHNOLOGY
  • OPINION
    • Corporate News from Media OutReach Newswire
  • HOME
  • BUSINESS
    • BANKING
    • FINANCE
    • INSURANCE
    • SME’s
    • REAL ESTATES
    • INVESTMENTS
    • ENERGY
    • RETAIL
  • CAPTAINS OF INDUSTRY
  • INNOVATION & ENTERPRISES
  • WOMEN & POWER
  • TECHNOLOGY
  • OPINION
    • Corporate News from Media OutReach Newswire
Watch Online
  • Home
  • Corporate News from Media OutReach Newswire
  • CK Life Sciences’ Sequencio Therapeutics Presents the Latest Vaccine Research Advancements at the American Association for Cancer Research Annual Meeting
  • Corporate News from Media OutReach Newswire

CK Life Sciences’ Sequencio Therapeutics Presents the Latest Vaccine Research Advancements at the American Association for Cancer Research Annual Meeting

Media OutReach Newswire March 31, 2026
HONG KONG SAR – Media OutReach Newswire – 31 March 2026 – Sequencio Therapeutics Company Limited (“Sequencio”), a subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CK Life Sciences”), today announced that five research abstracts will be presented at the American Association for Cancer Research (“AACR”) Annual Meeting 2026, taking place 17–22 April 2026 in San Diego, USA.

These presentations mark Sequencio’s first major scientific unveiling since its formation and showcase significant advancements in next‑generation cancer vaccine technologies based on Sequencio’s proprietary TrueHLA™ Epitope‑to‑Efficacy™ translational design framework, which enables rational, data‑driven vaccine development across circRNA, mRNA, peptide, and protein‑based platforms.

Collectively, Sequencio’s five AACR 2026 presentations highlight a consistent theme: rationally designed cancer vaccines that demonstrate robust immunogenicity and compelling anti‑tumour activity across multiple targets and modalities in preclinical models. These data underscore the strength of Sequencio’s approach to translating antigen selection into functional immune responses and tumour control. Building on this foundation, Sequencio is prioritizing its most promising programs for IND‑enabling studies, with the goal of accelerating select vaccine candidates into early‑stage clinical development through strategic partnerships and global collaboration.

Dr Melvin Toh, Vice President & Chief Scientific Officer of CK Life Sciences, expressed, “Sequencio’s cancer vaccine pipeline continues to advance with strong momentum. Our AACR 2026 presentations underscore both the scientific promise of our vaccines and the disciplined execution driving their progress. We look forward to building on this foundation as we advance next‑generation immunotherapies for patients.”

The AACR Annual Meeting is a gathering central to the global cancer research community, bringing together scientists, clinicians, other healthcare professionals, survivors, patients and advocates every year to share the latest breakthroughs and developments in cancer science and medicine. Last year, the 2025 Annual Meeting attracted 22,100 in-person participants from 85 countries.

Scientific Poster Presentations by Sequencio Therapeutics at AACR 2026

All five posters will be presented on 21 April 2026.

1. p53 Modified Shared Neoantigen Vaccine (Poster Number: 4361)

Title: Single amino acid residue substitution to improve immunogenicity of HLA peptides targeting p53 neoantigen

Authors: Chi Han Samson Li, Hong Wang, Kin Tak Chan, Genwei Zhang, Zhenghui Wang, Lipeng Lai, Melvin Toh

2. IGF1R Cancer Vaccine (Poster Number: 4368)

Title: Vaccine targeting IGF1R induces neutralizing antibody and robust anti‑tumor activity in a syngeneic mouse colon cancer model

Authors: Kenneth Nansheng Lin, Melvin Toh, Hong Wang

3. B7‑H3 Cancer Vaccine (Poster Number: 4369)

Title: B7-H3 vaccine induces robust humoral and cellular immunity and inhibits tumor growth in mice

Authors: Kenneth Nansheng Lin, Melvin Toh, Hong Wang

4. TROP2 circRNA + IL‑7 Combination Vaccine (Poster Number: 4370)

Title: TROP2‑circular RNA vaccine and IL7 synergistically inhibit TROP2+ tumor growth in mouse models

Authors: Zirong He, Yanan Li, Antong Li, Xiaoxuan Liu, Kenneth Nansheng Lin, Fan Yan Meng, Melvin Toh, Hong Wang

5. Claudin‑6 Cancer Vaccine (Poster Number: 4375)

Title: Claudin 6 vaccines effectively inhibit tumor growth in a syngeneic mouse colon cancer model

Authors: Na Wang, Lam Chow, Melvin Toh, Hong Wang

Hashtag: #CKLifeSciences #Sequencio #CancerVaccines #R&D #Pharmaceutical #AACR

The issuer is solely responsible for the content of this announcement.

CK Life Sciences Int’l., (Holdings) Inc.

CK Life Sciences Int’l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. With a mission of improving the quality of life, CK Life Sciences is engaged in healthcare research and development, with operating businesses that enable its R&D sustainability. Regarding pharmaceutical research and development, CK Life Sciences’ operations are focused on conducting research and development into cancer vaccines, RNA therapeutics and pain management solutions. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com.

Post navigation

Previous Bangkok announced as Host City of the inaugural Eurovision Song Contest Asia 2026
Next Linklogis Releases 2025 Annual Results: Total Volume of Processed Supply Chain Assets Exceeds RMB500 Billion, Unveiling the “SC+ Platform”

Related Stories

Indonesia and Chinese partners set out USD 63 billion in cooperation at APEC Shenzhen
  • Corporate News from Media OutReach Newswire

Indonesia and Chinese partners set out USD 63 billion in cooperation at APEC Shenzhen

November 18, 2026
APEC promo answers era’s question: Why does China lead global tech?
  • Corporate News from Media OutReach Newswire

APEC promo answers era’s question: Why does China lead global tech?

November 18, 2026
SenseTime Provides Business Update for the First Nine Months of 2026: Revenue Growth Accelerates, Gross Margin Continues to Improve and Full-Stack AI Commercialization Gathers Pace
  • Corporate News from Media OutReach Newswire

SenseTime Provides Business Update for the First Nine Months of 2026: Revenue Growth Accelerates, Gross Margin Continues to Improve and Full-Stack AI Commercialization Gathers Pace

November 18, 2026

Recent Comments

  • Absa Next unveils Investment Solutions featuring Absa Equity Fund on Absa Bank Kenya Unveils an Integrated Digital Finance Solution
  • ShafDB Closes 60 Billion Sustainable Bond to Finance Housing on S&P Global Ratings confirms ShafDB Sustainability Framework
  • Equity Group Plc delivers KES71.5Bn with 32pc growth Q3 2026 on Equity Group Plc Earnings Grows to KES45.5Bn Profit H1 2026
  • StanChart’s Signature CIO Funds earns 5-Star Morningstar Ratings on StanChart Bank Kenya Triumphs at Global Finance Awards 2026
  • DHL,RUBIS Energy Bring Shipping Services to Customers on Rubis Energy Kenya Eyes Boda Boda Sector through a Program

Connect with Us

  • WhatsApp
  • Facebook
  • Twitter
  • Youtube
  • LinkedIn
  • Instagram

You may have missed

Indonesia and Chinese partners set out USD 63 billion in cooperation at APEC Shenzhen
  • Corporate News from Media OutReach Newswire

Indonesia and Chinese partners set out USD 63 billion in cooperation at APEC Shenzhen

November 18, 2026
Jambojet Cuts Fuel Costs by 16pc through Data-Driven Operations
  • Air Safety
  • Aircraft
  • Airline
  • Aviation
  • Aviation Sector
  • BUSINESS
  • Flight
  • INNOVATION & ENTERPRISES
  • Investments
  • jets
  • Markets
  • operations
  • Professionals
  • Regional Markets

Jambojet Cuts Fuel Costs by 16pc through Data-Driven Operations

November 18, 2026
APEC promo answers era’s question: Why does China lead global tech?
  • Corporate News from Media OutReach Newswire

APEC promo answers era’s question: Why does China lead global tech?

November 18, 2026
GARVEE Launches 2026 Black Friday & Christmas Specials: Featuring Dream Holiday Gifts and Cozy Winter Living
  • Corporate News from Media OutReach Newswire

GARVEE Launches 2026 Black Friday & Christmas Specials: Featuring Dream Holiday Gifts and Cozy Winter Living

November 18, 2026

About Us

Our main focus is on quality Business news content that is verified and ready to be consumed by our users.

Our partners and readers alike are our heartbeat we value them in all that we do.

We offer an alternative as a mouthpiece to SMEs, entrepreneurs, and professionals on their daily long-term plans and milestone as well exchange the business ideas and success stories and to provide advertising services tailor-made to the needs and expectations of their products and services.

Join us in this endeavor to give you fast accurate and precise information as they develop.

 

 

Copyright ©2026 All rights reserved. | Businessquest by Geckoworks Ke_.